PriceTargets.com logo

Genprex - GNPX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 817.43%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.09 As of 12/3/2024 01:00 AM ET
▼ -0.01 (-0.91%)

This chart shows the closing price for GNPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Genprex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GNPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GNPX

Analyst Price Target is $10.00
▲ +817.43% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Genprex in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 817.43% upside from the last price of $1.09.

This chart shows the closing price for GNPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Genprex.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/25/2024HC WainwrightReiterated RatingBuy$10.00
1/30/2023Dawson JamesInitiated CoverageBuy$120.00
1/26/2021National SecuritiesInitiated CoverageBuy$280.00
5/26/2020Noble FinancialReiterated RatingBuy$200.00
4/22/2020Alliance Global PartnersInitiated CoverageBuy
(Data available from 12/4/2019 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Genprex logo
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.09
Low: $1.00
High: $1.10

50 Day Range

MA: $1.20
Low: $0.33
High: $3.59

52 Week Range

Now: $1.09
Low: $0.28
High: $14.40

Volume

369,802 shs

Average Volume

2,701,017 shs

Market Capitalization

$9.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Genprex?

The following Wall Street sell-side analysts have issued stock ratings on Genprex in the last twelve months: HC Wainwright.
View the latest analyst ratings for GNPX.

What is the current price target for Genprex?

0 Wall Street analysts have set twelve-month price targets for Genprex in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 817.4%. HC Wainwright has the highest price target set, predicting GNPX will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Genprex in the next year.
View the latest price targets for GNPX.

What is the current consensus analyst rating for Genprex?

Genprex currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GNPX will outperform the market and that investors should add to their positions of Genprex.
View the latest ratings for GNPX.

What other companies compete with Genprex?

Other companies that are similar to Genprex include ImmuCell, Elevation Oncology, Lantern Pharma, Carisma Therapeutics and Tonix Pharmaceuticals. Learn More about companies similar to Genprex.

How do I contact Genprex's investor relations team?

Genprex's physical mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company's listed phone number is (877) 774-4679 and its investor relations email address is [email protected]. The official website for Genprex is www.genprex.com. Learn More about contacing Genprex investor relations.